We respectfully acknowledge that the work to complete this rapid guidance document was hosted on Treaty 6 territory, a traditional gathering place for diverse Indigenous peoples including the Cree, Blackfoot, Metis, Nakota Sioux, Iroquois, Dene, Ojibway/Saulteaux/Anishinaabe, Inuit, and many others. We recognize that the ongoing criminalization, institutionalization, and discrimination against people who use substances disproportionately harm Indigenous Peoples, and that continuous efforts are needed to dismantle colonial systems of oppression. We are committed to the process of reconciliation with Indigenous Peoples, and recognize that it requires significant and ongoing changes to the health care system. We hope that this guidance document helps to reduce the harms faced by people who use substances in the COVID-19 pandemic.Funded by the Canadian Institutes of Health Research (CIHR), the Canadian Research Initiative in Substance Misuse (CRISM) is a national research-practice-policy network focused on substance use disorders, comprising four large interdisciplinary regional teams (Nodes) representing British Columbia, the Prairie Provinces, Ontario, and Quebec/Atlantic. Each CRISM node includes regional research scientists, service providers, policy makers, community leaders, and people with lived experience of substance use disorders. CRISM's mission is to translate the best scientific evidence into clinical practice, health services, and policy change. More information about CRISM can be found at:  document is one of a series of six national guidance documents, rapidly developed by the CRISM network at the request of the Government of Canada. Collectively, the six documents address urgent needs of people who use substances, service providers, and decision makers in relation to the COVID-19 pandemic. The urgent nature of this work required rapid development and dissemination of this guidance. This, and the continuing evolution of the knowledge base regarding COVID-19, precluded CRISM from conducting a comprehensive review of the relevant literature. However, when available, scientific evidence is cited in support of the expert advice offered herein. The guidance provided in this document is subject to change as new information becomes available. Readers should note that the intent of this document is to provide general guidance rather than detailed procedural and logistical advice. Readers are advised to consult local Public Health and medical authorities for specific input on navigating their own unique regulatory and policy environments, as necessary.# 
The CRISM/COVID-19 guidance documents cover the following topics:
- Supporting people who use substances in shelter settings during the COVID-19 pandemic - Telemedicine support for addiction services - Harm reduction worker safety - Recovery environments - Supporting people Who Use Substance in Acute Care Settings (this document)
- Strategies to Help Individuals Self-Isolate for People who use Drugs Completed documents may be accessed at: /. Each document was developed by a core CRISM authorship committee, drawing on expert knowledge, available scientific evidence, and a review of relevant documentation from Public Health authorities. Draft documents produced by each authorship committee were reviewed by pan-Canadian panels of content and clinical experts. People with lived and/or living experience of substance use have participated in the production of the CRISM/COVID-19 guidance document series, either as part of review or authorship committees. A CIHR Directed Operating Grant to CRISM provided funding for this work.